Collegium Pharmaceutical, Inc.
COLL
$35.69
$0.892.56%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 205.45M | 209.36M | 188.00M | 177.76M | 181.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 205.45M | 209.36M | 188.00M | 177.76M | 181.95M |
| Cost of Revenue | 24.66M | 21.66M | 22.19M | 21.48M | 24.22M |
| Gross Profit | 180.79M | 187.70M | 165.81M | 156.27M | 157.73M |
| SG&A Expenses | 63.61M | 65.55M | 72.70M | 76.42M | 58.65M |
| Depreciation & Amortization | 55.47M | 55.47M | 55.47M | 55.47M | 55.47M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.74M | 142.68M | 150.36M | 153.38M | 138.34M |
| Operating Income | 61.71M | 66.68M | 37.64M | 24.38M | 43.61M |
| Income Before Tax | 29.04M | 43.44M | 17.03M | 3.12M | 17.27M |
| Income Tax Expenses | 12.07M | 11.93M | 5.04M | 705.00K | 4.73M |
| Earnings from Continuing Operations | 16.96M | 31.51M | 11.98M | 2.42M | 12.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.96M | 31.51M | 11.98M | 2.42M | 12.54M |
| EBIT | 61.71M | 66.68M | 37.64M | 24.38M | 43.61M |
| EBITDA | 118.11M | 123.18M | 94.24M | 80.94M | 100.12M |
| EPS Basic | 0.54 | 1.00 | 0.38 | 0.08 | 0.39 |
| Normalized Basic EPS | 0.91 | 0.95 | 0.38 | 0.11 | 0.44 |
| EPS Diluted | 0.46 | 0.84 | 0.34 | 0.07 | 0.35 |
| Normalized Diluted EPS | 0.72 | 0.76 | 0.31 | 0.11 | 0.35 |
| Average Basic Shares Outstanding | 31.65M | 31.57M | 31.81M | 31.79M | 32.08M |
| Average Diluted Shares Outstanding | 40.08M | 39.44M | 39.08M | 32.84M | 40.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |